Onkologie. 2014:8(1):19-22

Radiotherapy of prostate cancer

Jan Dvořák
Ústav radiační onkologie Nemocnice Bulovka, 1. lékařská fakulta UK Praha

Radiotherapy of prostate cancer is one of the basic modalities of treatment. During the last years has undergone significant development

to enhance the effect of treatment with acceptable toxicity. The article describes the principles of radiotherapy, the primary division and

indications for various stages of the disease.

Keywords: radiotherapy, image-guided radiotherapy, intensity modulated radiotherapy, brachytherapy, external radiotherapy

Published: March 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dvořák J. Radiotherapy of prostate cancer. Onkologie. 2014;8(1):19-22.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side-effects of conformal and convetional radiotherapy in prostate cancer: a randomized trial. Lancet 1999; 353: 267-272. Go to original source... Go to PubMed...
    2. Hanlon AL, Watkins Bruner D, PeterR, Hanks GE. Quality of life study in prostaataee caancer patents treated with free-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symtoms to that of normal population. Int I Radiat Oncol Biol Phys 2001; 49: 51-59. Go to original source... Go to PubMed...
    3. Koper PC, Stroom JC, va Putten WL, et al Acute morbidity reducing using 3DCRT for prostate carcinoma: a randomized study. Int I Radiat Oncol Biol Phys 1999 43: 727-734. Go to original source... Go to PubMed...
    4. Michalski JM, Bae K, Roach M, et al. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from RTOG 9406 phase I/II dose escalation study. Int I Radiat Oncol Biol Phys 2010; 76: 14-22. Go to original source... Go to PubMed...
    5. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int I Radiat Oncol Biol Phys 2008; 70: 1124-1129. Go to original source... Go to PubMed...
    6. Jani AB, SU A, Correa D, Gratzle J. Comparison of la10:82- -86te gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versu conventional radiotherapy using localized fields. Prostate Cancer Prostatic Dis 2007; 10: 82-86. Go to original source... Go to PubMed...
    7. Bauman G, Rumble RB, Chen J, Loblaw A, Warde P. Members of the IMRT Indications Expert Panel. Ntensity-modulated radiotherapy in the treatment of prostate cancer. Clin Oncol 2012; 24: 461-473. Go to original source... Go to PubMed...
    8. Jacobs BL, Zhang Y, Skolarus TA, et al. Comparative effectiveness of external-beam radiation approaches for prostate cancer. Eur Urol 2014; 65: 162-168. Go to original source... Go to PubMed...
    9. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70: 67-74. Go to original source... Go to PubMed...
    10. Dirk Verellen et al. Review of Image-Guided Radiotherapy Techniques Oral presentation, ESTRO Conference Leepzig 2006.
    11. Coen JJ, Zietman AL. Proton radiation for localized prostate cancer. Nat Rev Urol 2009; 6: 324-330. Go to original source... Go to PubMed...
    12. Yu JB, Soulos PR, Herrin J, et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst 2013; 105: 25-32. Go to original source... Go to PubMed...
    13. Coen JJ, Paly JJ, Niemierko A, et al. Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int J Radiation Oncol Biol Phys 2012; 82: e201-209. Go to original source... Go to PubMed...
    14. Talcott JA, Rossi C, Shipley WU, et al. Patient-reported long-term outcomes after conventional and hig-dose combined proton and photon radiation for early prostate cancer. Jama 2010; 303: 1046-1053. Go to original source... Go to PubMed...
    15. Johansson S, Astr m L, Sandin F, et al. Hypofractionated proton boost combined with external beam radiotherapy for treatment localized prostate cancer. Prostate Cancer 2012: 654-668. Go to original source... Go to PubMed...
    16. Hoskin P. High dose rate brachytherapy for prostate cancer. Cancer Radiother 2008; 12: 512-514. Go to original source... Go to PubMed...
    17. Grills IS, Martinez AA, Hollander M, et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 2004; 171: 1098-1104. Go to original source... Go to PubMed...
    18. Vargas C, Ghilezan M, Hollander M, et al. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy. J Urol 2005; 174: 882-887. Go to original source... Go to PubMed...
    19. Potosky AL, Davis WW, Hofman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004; 96: 1358-1367. Go to original source... Go to PubMed...
    20. Sanda MG, Dun RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl J Med 2008; 358: 1250-1261. Go to original source... Go to PubMed...
    21. NCCN guidelines Version I. 2014.
    22. Thelis N, Tunn UW, Chatzikonstantinou G, at al. High dose brachytherapy as monotherapy for localised prostate cancer: a hypofrakcionated two-implant approach in 351 consecutive patients. Radiation Oncology 2013, 8: 115. Go to original source... Go to PubMed...
    23. EAU Guidelines 2014.
    24. Zelefsky MJ, Nedelka MA, Arican Z, et al. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: Reduced morbidity with an intraoperative brachytherapy planning technice and supplemental intensity-modulated radiation therapy. Brachytherapy 2008; 7: 1-6. Go to original source... Go to PubMed...
    25. Kupeliaan P, Kuban D, Thames H, et al. Improved biochemical relapse-free survival with increased external beam radiation doses in patients vith localized prostate cancer: combined experience of nine institution in patiens treeated in 1994 and 1995. Int J Radiat Oncol Biol Phys 2005; 61: 414-419. Go to original source... Go to PubMed...
    26. Xu N, Rossi PJ, Jani AB. Toxicity analysis of dose escalation from 75,6Gy to 81,0Gy in prostate cancer. Am J Clin Oncol 2011; 34: 11-15. Go to original source... Go to PubMed...
    27. Eade TN, Hanlon AL, Horwitz EM, et al. What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys 2007; 68: 682-668. Go to original source... Go to PubMed...
    28. D'Amico AV, Chen MH, Renhaw AA, et al. Androgen suppression and radiation vs radiation alone for prostate cancer: randomized trial JAMA 2008; 299: 289-295. Go to original source... Go to PubMed...
    29. Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from TROG 96.01 randomised trial. Lancet Oncol 2011; 12: 451-459. Go to original source... Go to PubMed...
    30. Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011; 365: 107-118. Go to original source... Go to PubMed...
    31. Roach M, 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J.Clin Oncol 2008; 26: 585-591. Go to original source... Go to PubMed...
    32. Warde P, Mason M Ding K, et al. Combined androgen deprivation therapy and radiation therapy for localy advanced prostate cancer: a randomized, phase 3 trial. Lancet 2011; 378: 2104-2111. Go to original source... Go to PubMed...
    33. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009; 373: 301-308. Go to original source... Go to PubMed...
    34. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomized study. Lancet Oncol 2010; 11: 1066-1073. Go to original source... Go to PubMed...
    35. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61: 1285-1290. Go to original source... Go to PubMed...
    36. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the durativ of elative androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26: 2497-2504. Go to original source... Go to PubMed...
    37. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516-2527. Go to original source... Go to PubMed...
    38. Sathya JR, Davis IR, Julian JA, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005; 23: 1192-1199. Go to original source... Go to PubMed...
    39. Shen X, Keith SW, Mishra MV, et al. The impal of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis. Int J Radiat Oncol Biol Phys 2012; 83: 1154-1159. Go to original source... Go to PubMed...
    40. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3NOMO prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009; 181: 956-962. Go to original source... Go to PubMed...
    41. Swanson GP, Goldman B, Tangen CM, et al. The prognostic impact of seminal vesicle involvement found at prostatectomy and the effect of adjutant radiation: data from Southwest Oncology Group 8794 J Urol 2008; 180: 2453-2457.
    42. Thompson IM, Jr., Tangen CM, Paradelo J, et al. Ajuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296: 2329-2335. Go to original source... Go to PubMed...
    43. Bolla M, Van Poppel H, Tombal B, et al. Postoperative radiotherapy after radiál prostatectomy for high-risk prostate cancer: long-term results of a randomized controlled trial (EORTC trial 22911) Lancet 2012; 380: 2018-2027. Go to original source... Go to PubMed...
    44. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radioteherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J.Clin Oncol 2009 27: 2924-2930. Go to original source... Go to PubMed...
    45. Van Praet Ch, Ost P, Lumen N, et al. Postoperative high-dose pelvic radiotherapy for N+ prostate cancer: Toxicity and matched case comparison with postoperative prostate bed-only radiotherapy Radiotherapy and Oncology 2013; 109: 22-228. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.